Systemic phenotype of sarcoidosis associated with radiological stages. Analysis of 1230 patients

Published:September 11, 2019DOI:


      • Sarcoidosis at diagnosis was limited to extrathoracic organs in 8% of patients.
      • Skin and neurological involvements were the most common isolated extrathoracic presentations.
      • Patients with Scadding stage I (isolated BHL) represented one third of patients.
      • The presence or absence of BHL played a weak role in driving significant phenotypic differences.
      • Stage IV (radiological evidence of lung fibrosis, 3% of patients) was associated with older age.



      To analyze the association between Scadding radiological stages of sarcoidosis at diagnosis and the disease phenotype (epidemiology, clinical presentation and extrathoracic involvement) in one of the largest cohorts of patients with sarcoidosis reported from southern Europe.


      The SARCOGEAS-Study Group includes a multicenter database of consecutive patients diagnosed with sarcoidosis according to the WASOG 1999 criteria. Extrathoracic disease at diagnosis was defined according to the 2014 instrument and the clusters proposed by Schupp et al.


      We analyzed 1230 patients (712 female, mean age 47 yrs.) who showed the following Scadding radiologic stages at diagnosis: stage 0 (n = 98), stage I (n = 395), stage II (n = 500), stage III (n = 195) and stage IV (n = 42). Women were overrepresented in patients presenting with extrathoracic/extrapulmonary disease, while the diagnosis was made at younger ages in patients presenting with BHL, and at older ages in those presenting with pulmonary fibrosis (q values <0.05). Multivariable adjusted analysis showed that patients presenting with pulmonary involvement (especially those with stages II and III) had a lower frequency of concomitant systemic involvement in some specific extrathoracic clusters (cutaneous-adenopathic/musculoskeletal, ENT and neuro-ocular/OCCC) but a higher frequency for others (hepatosplenic), in comparison with patients with extrapulmonary involvement (stages 0 and I). The presence of either BHL or fibrotic lesions did not influence the systemic phenotype of patients with pulmonary involvement.


      The key determinant associated with a differentiated systemic phenotype of sarcoidosis at diagnosis was interstitial pulmonary involvement rather than the individual Scadding radiological stage.


      WASOG (World Association of Sarcoidosis and Other Granulomatous Disorders), BHL (Bilateral hilar adenopathies), PI (Pulmonary infiltrates), ENT (ear, nose, and throat), CT (computed tomography), OCCC (oculo-cardiac-central nervous system-cutaneous)


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Baughman R.P.
        • Field S.
        • Costabel U.
        • et al.
        Sarcoidosis in America. analysis based on health care use.
        Ann Am Thorac Soc. 2016; 13: 1244-1252
        • Baughman R.P.
        • Lower E.E.
        • du Bois R.M.
        Lancet (London, England). 2003; 361: 1111-1118
        • Valeyre D.
        • Prasse A.
        • Nunes H.
        • Uzunhan Y.
        • Brillet P.-Y.
        • Muller-Quernheim J.
        Lancet (London, England). 2014; 383: 1155-1167
        • Pereira C.A.C.
        • Dornfeld M.C.
        • Baughman R.
        • Judson M.A.
        Clinical phenotypes in sarcoidosis.
        Curr Opin Pulm Med. 2014; 20: 496-502
        • Gerke A.K.
        Morbidity and mortality in sarcoidosis.
        Curr Opin Pulm Med. 2014; 20: 472-478
        • Culver D.A.
        • Baughman R.P.
        It's time to evolve from Scadding: phenotyping sarcoidosis.
        Eur Respir J. 2018; 51
        • Hunninghake G.W.
        • Costabel U.
        • Ando M.
        • et al.
        ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders.
        Sarcoidosis, Vasc Diffus lung Dis Off J WASOG / World Assoc Sarcoidosis Other Granulomatous Disord. 1999; 16: 149-173
        • Brito-Zeron P.
        • Sellares J.
        • Bosch X.
        • et al.
        Epidemiologic patterns of disease expression in sarcoidosis: age, gender and ethnicity-related differences.
        Clin Exp Rheumatol. 2016; 34: 380-388
        • Judson M.A.
        • Costabel U.
        • Drent M.
        • et al.
        The WASOG Sarcoidosis Organ Assessment instrument: an update of a previous clinical tool.
        Sarcoidosis, Vasc Diffus lung Dis Off J WASOG / World Assoc Sarcoidosis Other Granulomatous Disord. 2014; 31: 19-27
        • Brito-Zeron P.
        • Perez-Alvarez R.
        • Pallares L.
        • Retamozo S.
        • Baughman R.P.
        • Ramos-Casals M.
        Sarcoidosis: an update on current pharmacotherapy options and future directions.
        Expert Opin Pharmacother. 2016; 17: 2431-2448
        • Prasse A.
        • Katic C.
        • Germann M.
        • Buchwald A.
        • Zissel G.
        • Muller-Quernheim J.
        Phenotyping sarcoidosis from a pulmonary perspective.
        Am J Respir Crit Care Med. 2008; 177: 330-336
        • Schupp J.C.
        • Freitag-Wolf S.
        • Bargagli E.
        • et al.
        Phenotypes of organ involvement in sarcoidosis.
        Eur Respir J. 2018; 51
        • Inoue Y.
        • Inui N.
        • Hashimoto D.
        • et al.
        Cumulative incidence and predictors of progression in corticosteroid-naive patients with sarcoidosis.
        PLoS One. 2015; 10e0143371
        • SCADDING JG
        Prognosis of intrathoracic sarcoidosis in England. A review of 136 cases after five years' observation.
        Br Med J. 1961; 2: 1165-1172
        • Baughman R.P.
        • Nagai S.
        • Balter M.
        • et al.
        Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG task force.
        Sarcoidosis, Vasc Diffus lung Dis Off J WASOG. 2011; 28: 56-64
        • Takada K.
        • Ina Y.
        • Noda M.
        • Sato T.
        • Yamamoto M.
        • Morishita M.
        The clinical course and prognosis of patients with severe, moderate or mild sarcoidosis.
        J Clin Epidemiol. 1993; 46: 359-366
        • WURM K.
        The significance of stage classification of sarcoidosis Boeck's disease.
        Dtsch Med Wochenschr. 1960; 85: 1541-1548
        • Baughman R.P.
        • Judson M.A.
        • Teirstein A.
        • et al.
        Presenting characteristics as predictors of duration of treatment in sarcoidosis.
        QJM. 2006; 99: 307-315
        • Judson M.A.
        • Gilbert G.E.
        • Rodgers J.K.
        • Greer C.F.
        • Schabel S.I.
        The utility of the chest radiograph in diagnosing exacerbations of pulmonary sarcoidosis.
        Respirology. 2008; 13: 97-102
        • Yeager H.
        • Rossman M.D.
        • Baughman R.P.
        • et al.
        Pulmonary and psychosocial findings at enrollment in the ACCESS study.
        Sarcoidosis, Vasc Diffus lung Dis Off J WASOG. 2005; 22: 147-153
        • Drent M.
        • De Vries J.
        • Lenters M.
        • et al.
        Sarcoidosis: assessment of disease severity using HRCT.
        Eur Radiol. 2003; 13: 2462-2471
        • Judson M.A.
        • Boan A.D.
        • Lackland D.T.
        The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States.
        Sarcoidosis, Vasc Diffus lung Dis Off J WASOG / World Assoc Sarcoidosis Other Granulomatous Disord. 2012; 29: 119-127
        • Judson M.A.
        • Chopra A.
        • Conuel E.
        • et al.
        The assessment of cough in a sarcoidosis clinic using a validated instrument and a visual analog scale.
        Lung. 2017; 195: 587-594
        • Ors F.
        • Gumus S.
        • Aydogan M.
        • Sari S.
        • Verim S.
        • Deniz O.
        HRCT findings of pulmonary sarcoidosis; relation to pulmonary function tests.
        Multidiscip Respir Med. 2013; 8: 8
        • Aleksoniene R.
        • Zeleckiene I.
        • Mataciunas M.
        • et al.
        Relationship between radiologic patterns, pulmonary function values and bronchoalveolar lavage fluid cells in newly diagnosed sarcoidosis.
        J Thorac Dis. 2017; 9: 88-95
        • Danila E.
        • Jurgauskiene L.
        • Malickaite R.
        BAL fluid cells and pulmonary function in different radiographic stages of newly diagnosed sarcoidosis.
        Adv Med Sci. 2008; 53: 228-233
        • Chappell A.G.
        • Cheung W.Y.
        • Hutchings H.A.
        Sarcoidosis: a long-term follow up study.
        Sarcoidosis, Vasc Diffus lung Dis Off J WASOG. 2000; 17: 167-173
        • Kirkil G.
        • Lower E.E.
        • Baughman R.P.
        Predictors of mortality in pulmonary sarcoidosis.
        Chest. 2018; 153: 105-113
        • Judson M.A.
        • Thompson B.W.
        • Rabin D.L.
        • et al.
        The diagnostic pathway to sarcoidosis.
        Chest. 2003; 123: 406-412
        • James W.E.
        • Koutroumpakis E.
        • Saha B.
        • et al.
        Clinical features of extrapulmonary sarcoidosis without lung involvement.
        Chest. 2018; 154: 349-356
        • Ungprasert P.
        • Wetter D.A.
        • Crowson C.S.
        • Matteson E.L.
        Epidemiology of cutaneous sarcoidosis, 1976-2013: a population-based study from Olmsted County, Minnesota.
        J Eur Acad Dermatol Venereol. 2016; 30: 1799-1804
        • Fritz D.
        • van de Beek D.
        • Brouwer M.C.
        Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis.
        BMC Neurol. 2016; 16: 220
        • Mana J.
        • Rubio-Rivas M.
        • Villalba N.
        • et al.
        Multidisciplinary approach and long-term follow-up in a series of 640 consecutive patients with sarcoidosis: cohort study of a 40-year clinical experience at a tertiary referral center in Barcelona, Spain.
        Medicine (Baltimore). 2017; 96e7595
        • Darlington P.
        • Gabrielsen A.
        • Sorensson P.
        • et al.
        HLA-alleles associated with increased risk for extra-pulmonary involvement in sarcoidosis.
        Tissue Antigens. 2014; 83: 267-272
        • Piotrowski W.J.
        • Gorski P.
        • Pietras T.
        • Fendler W.
        • Szemraj J.
        The selected genetic polymorphisms of metalloproteinases MMP2, 7, 9 and MMP inhibitor TIMP2 in sarcoidosis.
        Med Sci Monit. 2011; 17: CR598-607
        • Baughman R.P.
        • Teirstein A.S.
        • Judson M.A.
        • et al.
        Clinical characteristics of patients in a case control study of sarcoidosis.
        Am J Respir Crit Care Med. 2001; 164 (Pt 1): 1885-1889
        • Sharma S.K.
        • Soneja M.
        • Sharma A.
        • Sharma M.C.
        • Hari S.
        Rare manifestations of sarcoidosis in modern era of new diagnostic tools.
        Indian J Med Res. 2012; 135: 621-629
        • Costabel U.
        • Hunninghake G.W.
        ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee American Thoracic Society European Respiratory Society World Association for Sarcoidosis and Other Granulomatous Disorders.
        Eur Respir J. 1999; 14: 735-737
        • Judson M.A.
        • Baughman R.P.
        • Costabel U.
        • et al.
        Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial.
        Eur Respir J. 2008; 31: 1189-1196
        • Criado E.
        • Sanchez M.
        • Ramirez J.
        • et al.
        Pulmonary sarcoidosis: typical and atypical manifestations at high-resolution CT with pathologic correlation.
        Radiographics. 2010; 30: 1567-1586
        • Lynch JP 3rd
        • Kazerooni E.A.
        • Gay S.E.
        Pulmonary sarcoidosis.
        Clin Chest Med. 1997; 18: 755-785